LOGIN
Investigating efficacy of extended-release steroid FX006 16mg and 32mg in knee OA treatment
May 2019
Investigating efficacy of extended-release steroid FX006 16mg and 32mg in knee OA treatment
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
A Phase IIb Trial of a Novel Extended-Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis
Arthritis Rheumatol. 2018 Feb;70(2):204-211. doi: 10.1002/art.40364Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
310 patients with Kellgren-Lawrence grade II-III knee osteoarthritis were randomized to a single intraarticular injection of either extended release triamcinolone acetonide 16mg (FX006 16mg; Flexion Therapeutics), extended release triamcinolone acetonide 32mg (FX006 32mg; Flexion Therapeutics), or placebo saline. Patients were assessed for the primary outcome measure of pain on a Numeric Rating Sc...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.